📰 Virtual Plenary News
Virtual Plenary News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Virtual Plenary. Real-time updates on events, politics, business and more.
June 2, 2024
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
December 11, 2023
GSK granted EC marketing authorisation for Jemperli plus chemotherapy
December 8, 2023
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...
October 31, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231. "We are excited about our pipeline progress and our...
October 20, 2023
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...
October 16, 2023
GSK positive CHMP opinion recommending Jemperli plus chemotherapy to treat endometrial cancer
September 14, 2023
Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...
August 9, 2023
Consolidated financial statements. In the preparation of the consolidated financial statements, amounts resulting from transactions between consolidated companies, including the equity...
July 31, 2023
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...
July 31, 2023
31.07.2023 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult ...